Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of Incyte Corporation. A complete text table follows the diagram.
A dominant U.S. hematology franchise supports a widening bench of dermatology, oncology and partnered medicines as JAKAFI approaches its 2028 patent cliff.
Swipe to explore
Every flow reproduces the filing's disaggregated revenue table. Product sales and royalties are expanded into the named medicines; milestone and contract revenue remains separate.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Incyte medicine portfolio | 1 | $1.3B | $1.273B quarterly revenue |
| Direct product sales | 2 | $1.1B | 87% of revenue |
| Partner royalties | 2 | $151M | 12% of revenue |
| Milestones & contracts | 2 | $17M | Collaboration economics |
| JAKAFI | 3 | $758M | U.S. hematology franchise |
| OPZELURA | 3 | $143M | Dermatology growth platform |
| Six other owned products | 3 | $204M | Oncology and hematology bench |
| JAKAVI royalties | 3 | $106M | Ex-U.S. ruxolitinib economics |
| OLUMIANT royalties | 3 | $36.4M | Partnered immunology |
| TABRECTA & other royalties | 3 | $9.2M | Additional partnered medicines |
| From | To | Value |
|---|---|---|
| Incyte medicine portfolio | Direct product sales | $1.1B |
| Incyte medicine portfolio | Partner royalties | $151M |
| Incyte medicine portfolio | Milestones & contracts | $17M |
| Direct product sales | JAKAFI | $758M |
| Direct product sales | OPZELURA | $143M |
| Direct product sales | Six other owned products | $204M |
| Partner royalties | JAKAVI royalties | $106M |
| Partner royalties | OLUMIANT royalties | $36.4M |
| Partner royalties | TABRECTA & other royalties | $9.2M |